Harvard Bioscience (HBIO) Invested Capital (2013 - 2025)

Harvard Bioscience (HBIO) has reported Invested Capital for 13 consecutive years, with $34.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Invested Capital rose 841.96% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at $68.8 million (down 14.22% YoY), while the FY2024 annual figure was $37.0 million, up 530.76% from the prior year.
• Invested Capital retreated to $34.0 million in Q3 2025 per HBIO's latest filing, from $34.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $37.0 million in Q4 2024 and bottomed at $2.0 million in Q1 2021.
• Historically, Invested Capital has averaged $10.0 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2021 — Invested Capital retreated 29.82% — and 2025, when it jumped 866.61%.
• Harvard Bioscience's Invested Capital stood at $3.2 million in 2021, then climbed by 17.81% to $3.8 million in 2022, then soared by 53.74% to $5.9 million in 2023, then soared by 530.76% to $37.0 million in 2024, then decreased by 8.09% to $34.0 million in 2025.
• Business Quant data shows HBIO's Invested Capital at $34.0 million in Q3 2025, $34.9 million in Q2 2025, and $36.0 million in Q1 2025.